|  |
| --- |
| Supplementary Table S3. Patient backgrounds in patients with drugs potentially associated with severe hypoglycemia classified as Categories I and II |
| 　 | whole | above | within the range  | inappropriately below | *P* value |
| n (%) | 199 | 82 (41.2) | 77 (38.7) | 40 (20.1) |  |
| Age (years) | 74 (70, 79) | 71 (69, 80) | 74 (69, 78) | 76 (72, 78) | 0.0662 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Number of female, n (%) | 88 (44.2) | 40 (48.8) | 34 (44.2) | 14 (35.0) | 0.3552 |
| BMI (kg/m2) | 24.4 (22.0, 26.9) | 25.5 (22.4, 28.7) | 23.6 (21.2, 25.7) | 23.5 (21.3, 26.5) | 0.0278\* |
| Diabetes duration (years) | 20 (12, 29) | 21 (13, 28) | 20 (10, 29) | 20 (14, 30) | 0.7873 |
| HbA1c (%) | 7.5 (6.9, 8.1) | 8.2 (7.9, 8.9) | 7.2 (7.0, 7.6) | 6.4 (6.1, 6.7) | <0.001\* |
| HbA1c (mmol/mol) | 58 (51, 65) | 66 (62, 73) | 55 (52, 59) | 46 (43, 49) | <0.001\* |
| FPG (mg/dL) | 146 (122, 178) | 160 (129, 200) | 138 (120, 157) | 135 (111, 162) | 0.0021\* |
| Fasting CPR (ng/mL) | 1.4 (0.7, 2.2) | 1.5 (0.6, 2.3) | 1.2 (0.6, 2.1) | 1.4 (0.9, 2.0) | 0.5296 |
| eGFR | 58.1 (45.4, 70.3) | 55.1 (44.1, 68.2) | 62.1 (49.2, 71.9) | 57.1 (46.1, 68.2) | 0.1222 |
| DASC-8 score, n (%) | 9 (8, 11) | 10 (8, 12) | 9 (8, 11) | 10 (8, 11) | 0.2269 |
| Category I | 135 (67.8) | 53 (64.6) | 56 (72.7) | 26 (65.0) |  |
| Category II | 64 (32.2) | 29 (35.4) | 21 (27.3) | 14 (35.0) | 0.5023 |
| Category III | 0 (0) | 0 (0) | 0 (0) | 0 (0) |  |
| Physically active (≥10METs/week), n (%) | 162 (81.4) | 63 (76.8) | 67 (87.0) | 32 (80.0) | 0.2483 |
| Complications, n (%) |  |  |  |  |  |
| Diabetic neuropathy | 146 (73.4) | 64 (78.1) | 57 (74.0) | 25 (62.5) | 0.1341 |
| Diabetic retinopathy | 84 (42.9) | 37 (45.7) | 32 (42.7) | 15 (37.5) | 0.6931 |
| Diabetic nephropathy | 115 (57.8) | 48 (58.5) | 40 (52.0) | 27 (67.5) | 0.2669 |
| Hypertension | 152 (76.4) | 67 (81.7) | 55 (71.4) | 30 (75.0) | 0.3044 |
| Dyslipidemia | 147 (73.9) | 65 (79.3) | 57 (74.0) | 25 (62.5) | 0.1410 |
| Stroke or TIA | 26 (13.1) | 14 (17.1) | 7 (9.1) | 5 (12.5) | 0.3260 |
| Cardiovascular disease | 42 (21.1) | 19 (23.2) | 15 (19.5) | 8 (20.0) | 0.8346 |
| Osteoporosis | 33 (16.6) | 18 (22.0) | 9 (11.7) | 6 (15.0) | 0.2107 |
| Malignancy | 53 (26.6) | 18 (22.0) | 20 (26.0) | 15 (37.5) | 0.1869 |
| Social conditions, n (%) |  |  |  |  | 0.1161 |
| Living with a partner | 108 (54.3) | 38 (46.3) | 48 (62.3) | 22 (55.0) |  |
| Living with children | 41 (20.6) | 24 (29.3) | 9 (11.7) | 8 (20.0) |  |
| Living with elder parents | 2 (1.0) | 1 (1.2) | 0 (0) | 1 (2.5) |  |
| Living alone | 46 (23.1) | 17 (20.7) | 20 (26.0) | 9 (22.5) |  |
| Nursing home stay | 2 (1.0) | 2 (2.4) | 0 (0) | 0 (0) |  |
| Diabetes treatment, n (%) |  |  |  |  |  |
| Drugs potentially associated with severe hypoglycemia | 199 (100) | 82 (100) | 77 (100) | 40 (100) |  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Insulin use | 134 (67.3) | 53 (64.6) | 55 (71.4) | 26 (65.0) | 0.6195 |
| Sulfonylurea | 52 (26.1) | 24 (29.3) | 20 (26.0) | 8 (20.0) | 0.5493 |
| Glinide | 47 (23.6) | 18 (22.0) | 19 (24.7) | 10 (25.0) | 0.8975 |
| α-glucosidase inhibitor | 29 (14.6) | 14 (17.1) | 11 (14.3) | 4 (10.0) | 0.5802 |
| Metformin | 93 (46.7) | 41 (50.0) | 33 (42.9) | 19 (47.5) | 0.6618 |
| Thiazolidine | 10 (5.0) | 3 (3.7) | 5 (6.5) | 2 (5.0) | 0.7158 |
| GLP‐1 receptor agonist | 44 (22.1) | 27 (32.9) | 13 (16.9) | 4 (10.0) | 0.0061\* |
| DPP-4 inhibitor | 117 (58.8) | 41 (50.0) | 47 (61.0) | 29 (72.5) | 0.0529 |
| SGLT2 inhibitor | 51 (25.6) | 26 (31.7) | 21 (27.3) | 4 (10.0) | 0.0330\* |
| Injecting oneself | 137 (93.2) | 56 (90.3) | 54 (94.7) | 27 (96.4) | 0.4765 |
| Number of concomitant antidiabetic drugs, n | 3 (2, 4) | 3 (2, 4) | 3 (2, 4) | 3 (2, 3) | 0.2366 |

Values are expressed as median (interquartile range) or number (%) of patients in each category. The Kruskal-Wallis test or chi-square test was used for comparisons of the parameters.

BMI: body mass index; FPG: fasting plasma glucose; CPR: C-peptide; eGFR: estimated glomerular filtration rate; GLP‐1: glucagon‐like peptide‐1; DPP‐4: dipeptidyl peptidase‐4; SGLT2: sodium-glucose cotransporter 2; TIA: transient ischemic attack